Brind.

Novavax faces an uncertain outlook regarding its vaccine programs, as reported by Bank of America.

1 report, 1 independent Updated Aug 20
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Novavax faces an uncertain outlook regarding its vaccine programs, as reported by Bank of America.

Who's involved

What this event is mainly about

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • Investing.comBofA downgrades Novavax stock on vaccine uncertainty Investing.com -- Bank of America cut its rating on Novavax (NASDAQ:NVAX) to Underperform from Neutral and lowered its price objective to $7 from $